|
Jul 30
|
Bullish Larimar Therapeutics Insiders Loaded Up On US$540.7k Of Stock
|
|
May 20
|
Larimar Therapeutics Announces FDA has Removed Partial Clinical Hold for Nomlabofusp Program in Friedreich’s Ataxia
|
|
May 10
|
Companies Like Larimar Therapeutics (NASDAQ:LRMR) Are In A Position To Invest In Growth
|
|
May 9
|
Larimar Therapeutics Reports First Quarter 2024 Operating and Financial Results
|
|
Mar 14
|
Larimar Therapeutics Inc (LRMR) Reports Full Year and Q4 2023 Financial Results
|
|
Mar 14
|
Larimar Therapeutics Reports Fourth Quarter and Full Year 2023 Operating and Financial Results and Provides Update on Nomlabofusp Development
|
|
Mar 11
|
Larimar Therapeutics Announces the Dosing of the First Patient in Long-term Open Label Extension Study for Nomlabofusp in Patients with Friedreich’s Ataxia
|
|
Mar 6
|
Larimar Therapeutics to Present at the Leerink Partners Global Biopharma Conference
|
|
Dec 9
|
With 45% ownership, Larimar Therapeutics, Inc. (NASDAQ:LRMR) has piqued the interest of hedge funds investors
|
|
Aug 7
|
Larimar Therapeutics Insiders Placed Bullish Bets Worth US$1.2m
|